EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer

Akshara Singareeka Raghavendra iD, Senthil Damodaran iD, Carlos H Barcenas iD, Suzanne A Fuqua iD, Rachel M Layman iD, Debu Tripathy iD

CA: A Cancer Journal for Clinicians · 2026-01 · 76 (1)

DOI: 10.3322/caac.70055 ↗

At a glance

Übersichtsarbeit in CA: A Cancer Journal for Clinicians, published online on 2026-01-12. Written by Akshara Singareeka Raghavendra and 5 co-authors. Institution: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Major MEDLINE topics: Breast Neoplasms, Precision Medicine. Cited 11 times so far (Crossref); 194 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCI NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The hormone receptor (HR)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer subtype accounts for most early and metastatic breast cancer (MBC) cases. HR‐positive/HER2‐negative MBC is characterized by a relatively prolonged, although variable, disease course and substantial intertumoral and intratumoral heterogeneity. Although endocrine‐based therapies remain the cornerstone of treatment, nearly all patients eventually develop resistance, which is increasingly addressed with biologically targeted agents and newer‐generation cytotoxic drugs. This review summarizes the current understanding of HR‐positive/HER2‐negative MBC biology, highlighting mechanisms of intrinsic and acquired resistance, including driver genomic alterations that, along with clinical factors, help guide therapeutic choices and sequencing. The authors specify and discuss how genomic and transcriptomic profiling inform treatment selection and how side effects and overall patient experience are considered in decision making. Advances in targeted therapies, such as CDK4/6 (cyclin‐dependent kinase 4/6), PI3K (phosphatidylinositol 3‐kinase), and AKT (protein kinase B) inhibitors, and next‐generation estrogen receptor degraders are reviewed along with the expanding role of antibody–drug conjugates and biomarker‐guided tumor‐agnostic biologic therapies. The authors also explore evolving biologic concepts, including the impact of the tumor microenvironment on resistance and disease progression, and consider the distinct clinical behavior of invasive lobular carcinoma and current approaches. Emerging data from contemporary clinical trials promise to refine clinical and biomarker‐driven algorithms and improve outcomes for patients with HR‐positive/HER2‐negative MBC. Ongoing multi‐omic research and adaptive clinical strategies will be essential to further the application of precision oncology in this most common subtype of MBC. Importantly, patient‐reported outcomes, shared decision making, and real‐world evidence are increasingly useful in formulating comprehensive care plans, guidelines, and policy. The modern treatment landscape features a personalized approach that integrates clinical features, biomarkers, and patient preferences across the disease continuum.

Subjects

MeSH terms (MEDLINE)

Breast NeoplasmsPrecision MedicineHumansFemaleErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenDrug Resistance, NeoplasmMolecular Targeted TherapyReceptors, ProgesteroneBiomarkers, Tumor

Author keywords

antibody–drug conjugates (ADCs)cyclin‐dependent kinase 4/6 inhibitors (CDK4/6is)endocrine resistancehormone receptor (HR)‐positive/human epidermal growth factor receptor 2 (HER2)‐…patient‐related outcomes (PROs)selective estrogen receptor degraders (SERDs)signal transduction phosphatidylinositol 3‐kinase/protein kinase B/mammalian ta…

Substances

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, humanBiomarkers, Tumor

Authors and institutions

  • Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

ORCID profiles: Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos H Barcenas, Suzanne A Fuqua, Rachel M Layman, Debu Tripathy

Funding

  • NCI NIH HHS

Cite

APA

Singareeka Raghavendra, A., Damodaran, S., Barcenas, C. H., Fuqua, S. A., Layman, R. M., & Tripathy, D. (2026). Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer. CA: A Cancer Journal for Clinicians, 76(1). https://doi.org/10.3322/caac.70055

Vancouver

Singareeka Raghavendra A, Damodaran S, Barcenas CH, Fuqua SA, Layman RM, Tripathy D. Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer. CA: A Cancer Journal for Clinicians. 2026;76(1). doi:10.3322/caac.70055

BibTeX
@article{SingareekaRaghavendra2026,
  author = {Singareeka Raghavendra, Akshara and Damodaran, Senthil and Barcenas, Carlos H and Fuqua, Suzanne A and Layman, Rachel M and Tripathy, Debu},
  title = {Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2026},
  volume = {76},
  number = {1},
  doi = {10.3322/caac.70055}
}
Start for free →